Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A S Wierzbicki

Showing results (1-10 of 184) with videos related to

Pageof 19
Sort By:
International Journal of Clinical Practice|December 16, 2010
Cardiovascular screening: which populations, what measures of risk?A S Wierzbicki
International Journal of Clinical Practice|August 19, 2010
Comparing apples and pears: assessment of lipid-lowering therapies differentiated by side effectsA S Wierzbicki
International Journal of Clinical Practice|March 16, 2011
Niacin: the only vitamin that reduces cardiovascular eventsA S Wierzbicki
International Journal of Clinical Practice|August 31, 2006
Lipid lowering, statins and cancerA S Wierzbicki
International Journal of Clinical Practice|December 21, 2004
Lipid-altering agents: the futureA S Wierzbicki
International Journal of Clinical Practice|May 27, 1999
The role of lipid lowering in transplantationA S Wierzbicki
The New England Journal of Medicine|May 6, 1993
Antibodies to L-type calcium channels in amyotrophic lateral sclerosisA S Wierzbicki
BMJ (Clinical Research Ed.)|January 30, 1993
Paget's disease of boneA S Wierzbicki
International Journal of Clinical Practice|August 21, 2009
Storms, tea cups and the adverse effects of statinsA S Wierzbicki
Lupus|April 24, 2001
Lipid-lowering drugs in lupus: an unexplored therapeutic interventionA S Wierzbicki
Pageof 19

Showing results (1-10 of 184) with videos related to

Sort By:
Pageof 19
International Journal of Clinical Practice|December 16, 2010
Cardiovascular screening: which populations, what measures of risk?A S Wierzbicki
International Journal of Clinical Practice|August 19, 2010
Comparing apples and pears: assessment of lipid-lowering therapies differentiated by side effectsA S Wierzbicki
International Journal of Clinical Practice|March 16, 2011
Niacin: the only vitamin that reduces cardiovascular eventsA S Wierzbicki
International Journal of Clinical Practice|August 31, 2006
Lipid lowering, statins and cancerA S Wierzbicki
International Journal of Clinical Practice|December 21, 2004
Lipid-altering agents: the futureA S Wierzbicki
International Journal of Clinical Practice|May 27, 1999
The role of lipid lowering in transplantationA S Wierzbicki
The New England Journal of Medicine|May 6, 1993
Antibodies to L-type calcium channels in amyotrophic lateral sclerosisA S Wierzbicki
BMJ (Clinical Research Ed.)|January 30, 1993
Paget's disease of boneA S Wierzbicki
International Journal of Clinical Practice|August 21, 2009
Storms, tea cups and the adverse effects of statinsA S Wierzbicki
Lupus|April 24, 2001
Lipid-lowering drugs in lupus: an unexplored therapeutic interventionA S Wierzbicki
Pageof 19